lncRNA MT1JP‑overexpression abolishes the silencing of PTEN by miR‑32 in hepatocellular carcinoma

Zhang,Shuhua; Xu,Jianqun; Chen,Qing; Zhang,Fan; Wang,Hongjuan; Guo,Hongrong

doi:10.3892/ol.2021.12865

lncRNA MT1JP‑overexpression abolishes the silencing of PTEN by miR‑32 in hepatocellular carcinoma

Authors:
- Shuhua Zhang
- Jianqun Xu
- Qing Chen
- Fan Zhang
- Hongjuan Wang
- Hongrong Guo
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Respiratory Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: June 15, 2021 https://doi.org/10.3892/ol.2021.12865
Article Number: 604
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have shown that long non‑coding RNA (lncRNA) MT1JP plays a role as a tumor suppressor in several types of cancer. The present study aimed to explore the role of MT1JP in hepatocellular carcinoma (HCC). Paired HCC and non‑tumor tissues from 64 patients with HCC were subjected to RNA isolation and reverse transcription‑quantitative PCR (RT‑qPCR) to analyze the differential expression of MT1JP, microRNA (miR)‑32 and phosphatase and tensin homolog (PTEN) in HCC. Cell transfections, followed by RT‑qPCR and western blotting, were carried out to investigate the interactions among MT1JP, miR‑32 and PTEN. The role of MT1JP, miR‑32 and PTEN in regulating HCC cell proliferation was assessed using a Cell Counting Kit‑8 assay. It was found that MT1JP was downregulated in HCC cancer tissues compared with that in non‑cancer tissues. Survival analysis showed that patients with low MT1JP expression levels exhibited a significantly higher 5‑year overall survival rate compared with patients with high MT1JP levels. The expression of MT1JP in HCC tissues was positively associated with PTEN and negatively associated with miR‑32. Overexpression of MT1JP increased the expression levels of PTEN and decreased the expression levels of miR‑32. Overexpression of miR‑32 did not affect the expression of MT1JP but decreased the expression levels of PTEN and attenuated the effect of overexpression of MT1JP on the expression of PTEN. Overexpression of MT1JP and PTEN decreased the proliferation of HCC cells. Overexpression of miR‑32 played an opposite role and attenuated the effects of overexpression of MT1JP. Therefore, MT1JP may upregulate PTEN by downregulating miR‑32 to regulate HCC cell proliferation.

View Figures

View References

1	Chen Z, He M, Chen J, Li C and Zhang Q: Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a/SIRT1 axis in liver cancer. Oncol Lett. 20:893–901. 2020. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Xu J and Xu Y: The lncRNA MEG3 downregulation leads to osteoarthritis progression via miR-16/SMAD7 axis. Cell Biosci. 7:692017. View Article : Google Scholar : PubMed/NCBI
5	Liu J, Tang T, Wang GD and Liu B: lncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARgamma axis in non-alcoholic fatty liver disease. Biosci Rep. 39:BSR201817222019. View Article : Google Scholar : PubMed/NCBI
6	Yang CA, Li JP, Yen JC, Lai IL, Ho YC, Chen YC, Lan JL and Chang JG: lncRNA NTT/PBOV1 axis promotes monocyte differentiation and is elevated in rheumatoid arthritis. Int J Mol Sci. 19:28062018. View Article : Google Scholar : PubMed/NCBI
7	Harries LW: Long non-coding RNAs and human disease. Biochem Soc Trans. 40:902–906. 2012. View Article : Google Scholar : PubMed/NCBI
8	Jiang MC, Ni JJ, Cui WY, Wang BY and Zhuo W: Emerging roles of lncRNA in cancer and therapeutic opportunities. Am J Cancer Res. 9:1354–1366. 2019.PubMed/NCBI
9	Wang Z, Huang D, Huang J, Nie K, Li X and Yang X: lncRNA TMPO-AS1 exerts oncogenic roles in HCC through regulating miR-320a/SERBP1 Axis. Onco Targets Ther. 13:6539–6551. 2020. View Article : Google Scholar : PubMed/NCBI
10	Teng F, Zhang JX, Chang QM, Wu XB, Tang WG, Wang JF, Feng JF, Zhang ZP and Hu ZQ: lncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 39:2352020. View Article : Google Scholar : PubMed/NCBI
11	Liu X, Peng D, Cao Y, Zhu Y, Yin J, Zhang G, Peng X and Meng Y: Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis. Cancer Gene Ther. 28:486–501. 2021. View Article : Google Scholar : PubMed/NCBI
12	Wei F, Yang L, Jiang D, Pan M, Tang G, Huang M and Zhang J: Long noncoding RNA DUXAP8 contributes to the progression of hepatocellular carcinoma via regulating miR-422a/PDK2 axis. Cancer Med. 9:2480–2490. 2020. View Article : Google Scholar : PubMed/NCBI
13	Komoll RM, Hu Q, Olarewaju O, von Döhlen L, Yuan Q, Xie Y, Tsay HC, Daon J, Qin R, Manns MP, et al: MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma. J Hepatol. 74:122–134. 2021. View Article : Google Scholar : PubMed/NCBI
14	Zhang Y, Pan Q and Shao Z: Tumor-Suppressive role of microRNA-202-3p in hepatocellular carcinoma through the KDM3A/HOXA1/MEIS3 pathway. Front Cell Dev Biol. 8:5560042021. View Article : Google Scholar : PubMed/NCBI
15	Zhao L, Han T, Li Y, Sun J, Zhang S, Liu Y, Shan B, Zheng D and Shi J: The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. FASEB J. 31:893–903. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Wang J, An W, Chen C, Wang W, Zhu C, Chen F, Chen H, Zheng W and Gong J: MiR-32 inhibits proliferation and metastasis by targeting EZH2 in glioma. Technol Cancer Res Treat. 18:15330338198541322019. View Article : Google Scholar : PubMed/NCBI
17	Liu YJ, Zhou HG, Chen LH, Qu DC, Wang CJ, Xia ZY and Zheng JH: MiR-32-5p regulates the proliferation and metastasis of cervical cancer cells by targeting HOXB8. Eur Rev Med Pharmacol Sci. 23:87–95. 2019.PubMed/NCBI
18	Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
19	Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009. View Article : Google Scholar : PubMed/NCBI
20	Yan SY, Chen MM, Li GM, Wang YQ and Fan JG: MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. Tumour Biol. 36:4747–4755. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhang Y, Zhu Z, Huang S, Zhao Q, Huang C, Tang Y, Sun C, Zhang Z, Wang L, Chen H, et al: lncRNA XIST regulates proliferation and migration of hepatocellular carcinoma cells by acting as miR-497-5p molecular sponge and targeting PDCD4. Cancer Cell Int. 19:1982019. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Liu L, Yue H, Liu Q, Yuan J, Li J, Wei G, Chen X, Lu Y, Guo M, Luo J and Chen R: lncRNA MT1JP functions as a tumor suppressor by interacting with TIAR to modulate the p53 pathway. Oncotarget. 7:15787–15800. 2016. View Article : Google Scholar : PubMed/NCBI
24	Xu Y, Zhang G, Zou C, Zhang H, Gong Z, Wang W, Ma G, Jiang P and Zhang W: lncRNA MT1JP suppresses gastric cancer cell proliferation and migration through MT1JP/miR-214-3p/RUNX3 axis. Cell Physiol Biochem. 46:2445–2459. 2018. View Article : Google Scholar : PubMed/NCBI
25	Chen J, Lou J, Yang S, Lou J, Liao W, Zhou R, Qiu C and Ding G: MT1JP inhibits glioma progression via negative regulation of miR-24. Oncol Lett. 19:334–342. 2020.PubMed/NCBI
26	Yu H, Wang S, Zhu H and Rao D: lncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer. J Cell Physiol. Feb 20–2019.(Epub ahead of print). doi: 10.1002/jcp.28274. View Article : Google Scholar
27	Wu JH, Xu K, Liu JH, Du LL, Li XS, Su YM and Liu JC: lncRNA MT1JP inhibits the malignant progression of hepatocellular carcinoma through regulating AKT. Eur Rev Med Pharmacol Sci. 24:6647–6656. 2020.PubMed/NCBI
28	Chen CY, Chen J, He L and Stiles BL: PTEN: Tumor suppressor and metabolic regulator. Front Endocrinol (Lausanne). 9:3382018. View Article : Google Scholar : PubMed/NCBI
29	Gao X, Qin T, Mao J, Zhang J, Fan S, Lu Y, Sun Z, Zhang Q, Song B and Li L: PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway. J Exp Clin Cancer Res. 38:2562019. View Article : Google Scholar : PubMed/NCBI
30	Wang YN, Xu F, Zhang P, Wang P, Wei YN, Wu C and Cheng SJ: MicroRNA-575 regulates development of gastric cancer by targeting PTEN. Biomed Pharmacother. 113:1087162019. View Article : Google Scholar : PubMed/NCBI
31	Gao ZQ, Wang JF, Chen DH, Ma XS, Wu Y, Tang Z and Dang XW: Long non-coding RNA GAS5 suppresses pancreatic cancer metastasis through modulating miR-32-5p/PTEN axis. Cell Biosci. 7:662017. View Article : Google Scholar : PubMed/NCBI
32	Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S and Mak TW: Regulation of PTEN transcription by p53. Mol Cell. 8:317–325. 2001. View Article : Google Scholar : PubMed/NCBI